Statins are among the most commonly prescribed medications worldwide, used primarily to lower cholesterol and reduce the risk of cardiovascular disease. While statins are generally safe and well-tolerated, like all medications, they can cause side effects in some individuals. Understanding these side effects can help patients make informed decisions and discuss concerns with their healthcare providers.
1. Muscle Pain and Weakness
The most frequently reported side effect of statins is muscle-related symptoms, including pain, tenderness, and weakness. This condition, known as statin-associated muscle symptoms (SAMS), affects about 5-10% of users in real-world settings, though the rate appears lower in clinical trials [1].
2. Liver Enzyme Elevations
Statins can occasionally cause an increase in liver enzymes, which may indicate liver inflammation. This side effect is rare and typically reversible upon discontinuation or dose adjustment. Routine liver function tests are often recommended during treatment [2].
3. Digestive Issues
Some patients report gastrointestinal side effects such as nausea, constipation, diarrhea, or abdominal pain. These symptoms are usually mild and tend to resolve with time or dosage adjustments [3].
4. Increased Blood Sugar Levels
Statin use has been linked to a slight increase in blood sugar levels, which can potentially lead to type 2 diabetes, especially in individuals already at risk. Despite this, the cardiovascular benefits of statins generally outweigh this risk [4].
5. Memory and Cognitive Effects
There have been anecdotal reports of memory loss or confusion with statin use, but extensive research has not found strong evidence to support a causal link. The FDA has noted these reports but considers them rare and reversible [5].
References
- Stroes ES, et al. (2015). Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement. European Heart Journal, 36(17), 1012–1022.
- Stone NJ, et al. (2014). 2013 ACC/AHA guideline on the treatment of blood cholesterol. Journal of the American College of Cardiology, 63(25 Pt B), 2889–2934.
- Ward NC, et al. (2019). Statin-related adverse events in primary prevention: a systematic review and meta-analysis of randomized controlled trials. American Journal of Cardiology, 123(5), 736–745.
- Sattar N, et al. (2010). Statins and risk of incident diabetes: a collaborative meta-analysis of randomized statin trials. Lancet, 375(9716), 735–742.
- U.S. Food and Drug Administration (2012). FDA Drug Safety Communication: Important safety label changes to cholesterol-lowering statin drugs. https://www.fda.gov/